Explore 3 Stock Ideas & Industry Insights Download Free Report

News

Why Is Regencell Bioscience (NASDAQ:RGC) Stock Up 9% Today?

Regencell Bioscience Holdings (NASDAQ:RGC) shares are rebounding sharply, pulling further off their 52-week low near $4.51. Regencell is a Hong Kong-based early-stage bioscience company specializing in Traditional Chinese Medicine, focused on the research, development, and commercialization of TCM-based liquid formulae designed to treat neurocognitive …

Nitish Kishor | 02 September 2026

Why Is Sarepta Therapeutics (NASDAQ:SRPT) Stock Up 8% Today?

Sarepta Therapeutics (NASDAQ:SRPT) shares are climbing further, extending a rebound that began last week, as investor sentiment improves ahead of anticipated late-2026 clinical data readouts for the company's mid-stage muscle disease programs in facioscapulohumeral muscular dystrophy and myotonic dystrophy. Sarepta is a Cambridge, Massachusetts-based …

Nitish Kishor | 02 September 2026

Why Is Novo Nordisk (NYSE:NVO) Stock Up 3% Today?

Novo Nordisk (NYSE:NVO) shares are rebounding sharply following the recent launch of its oral Wegovy weight-loss pill in Germany and Greater China. Novo Nordisk is a Danish global healthcare company founded in 1923, headquartered in Bagsvaerd, Denmark, operating primarily through its Diabetes and Obesity …

Nitish Kishor | 02 September 2026

Why Is Alumis (NASDAQ:ALMS) Stock Up 11% Today?

Alumis (NASDAQ:ALMS) shares are rebounding sharply, clawing back a portion of Monday's roughly 57% crash that followed disappointing Phase 2b LUMUS trial results for lead candidate envdeucitinib in systemic lupus erythematosus. Alumis is a South San Francisco-based clinical-stage biopharmaceutical company developing precision medicines for …

Nitish Kishor | 02 September 2026

Alnylam Pharmaceuticals (NASDAQ:ALNY) Surges 8% on Positive ESC Congress Data

Alnylam Pharmaceuticals (NASDAQ:ALNY) shares are surging as investors digest strongly positive data presented at the European Society of Cardiology Congress, reinforcing the clinical profile of vutrisiran, marketed as Amvuttra, across patients with transthyretin amyloid cardiomyopathy. Alnylam is a Cambridge, Massachusetts-based biopharmaceutical company and pioneer …

Nitish Kishor | 02 September 2026

This NYSE Medical Device Stock Falls 8% Today Even After a High-Profile AI Partnership

Butterfly Network (NYSE:BFLY) is trading sharply lower today even after announcing a multi-year licensing agreement with a well-funded brain-computer interface startup, a reaction that runs counter to what would typically be viewed as positive news. The company is a Burlington, Massachusetts-based digital health company …

Nitish Kishor | 02 September 2026

Faeth Therapeutics (NASDAQ:FTH) Surges 12% to a 52-Week High on Pipeline Momentum

Faeth Therapeutics (NASDAQ:FTH) shares surged to a new 52-week high as clinical-stage catalysts drew heightened investor engagement ahead of a busy September investor conference schedule. Faeth is an Austin, Texas-based clinical-stage oncology company focused on improving outcomes for cancer patients through multi-node inhibition of …

Nitish Kishor | 02 September 2026

Why Is Geron (NASDAQ:GERN) Penny Stock Up 6% Today?

Geron (NASDAQ:GERN), a penny stock trading under $2 per share, is surging today on well-above-average volume, even as broader markets and the healthcare sector face pressure from rising bond yields and Middle East-driven oil spikes. Geron is a commercial-stage biopharmaceutical company headquartered in Foster …

Nitish Kishor | 02 September 2026

Can Regis's (NASDAQ:RGS) Supercuts Turnaround Offset a Shrinking Franchise Base?

Regis Corporation (NASDAQ:RGS), the Minneapolis based franchisor of hair salon brands including Supercuts, SmartStyle, and Cost Cutters, closed fiscal 2026 with revenue of 224.5 million dollars and adjusted EBITDA of 32.8 million dollars, up from 31.6 million dollars in the prior year. Consolidated same-store …

Nitish Kishor | 02 September 2026

Zepp Health (NYSE:ZEPP) Margin Improves as Wearables Portfolio Shifts Upmarket

Zepp Health Corporation (NYSE:ZEPP), the Netherlands headquarteredParent Companyof the Amazfit smart wearables brand, reported second quarter 2026 revenue of 63.5 million dollars, up 6.9 percent year over year, with gross margin improving 120 basis points to 37.4 percent despite higher memory and other component …

Nitish Kishor | 02 September 2026
Support

Hi! How can we help you today?

Loading…